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SUMMARY
The prevalence ofknown cases ofacromegaly in Northern Ireland in 1984 was
6 3 per 100,000 population. The incidence ofnewly-diagnosed cases over the
preceding 25 years was 5 5 patients per year, or 0 4 patients per 100,000
population per year. This rate would be equivalent to about 200 new cases per
year in the United Kingdom.
Four options have been available to most of these patients - surgical hypo-
physectomy (transfrontal or transsphenoidal), pituitary radiotherapy (usually
external cobalt beam), drug treatment with bromocriptine, or no treatment.
Choice of treatment has been mainly influenced by tumour size, with the larger
pituitary adenomas having surgery initially. No singleform oftreatment has been
successful in achieving a clinical remission or cure in more than a minority of
cases. The most successful outcome has been where total pituitary ablation has
been achieved.
Life-table analysis for the whole group shows life expectancy which is not
markedly different for that ofan age-matchedpopulation from Northern Ireland.
Morbidity related to long term osteoarthritis and treatment complications remain
a major problem. The incidence of malignant tumours is higher than would be
expected.
INTRODUCTION
The natural history of a chronic endocrine condition can be measured both by
morbidity and mortality. While there have been several reviews of the experience
of the management of acromegaly in patients referred to large endocrine units
serving widely scattered and mobile populations, only the series from Newcastle-
upon-Tyne1 approachesacomplete ascertainmentofacromegaly inacommunity.
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Treatment for acromegaly in different centres in the past 25 years has included
direct surgical approach to the pituitary by the transfrontal or transsphenoidal
route, radiotherapy using a standard cobalt unit or linear accelerator, and more
recently drug therapy with bromocriptine or somatostatin. Some patients have
had no pituitary-directed treatment. The choice of treatment has depended as
much on available local expertise and facilities as on any defined protocol, and
many recorded series are based on one particular treatment.2 In Belfast we have
been able to study all patients diagnosed to have acromegaly in Northern Ireland
(population 1 -5 million) during a 25 year period and to achieve 100% review. All
treatment options have been equally available (except for a linear accelerator)
and there has been close co-operation between the endocrine, the neurosurgical
and the radiotherapy clinics. The long term review of all patients has been at the
endocrine clinic.
METHODS
Records for 131 acromegalic patients were available for study. Since 1959
virtually all patients diagnosed to have clinical acromegaly in Northern Ireland
have been seen by DRH. In the early years some of these patients had already
been treated by radiotherapy or transfrontal hypohysectomy.
In 1984, 86 patients (65-6%) were still attending the endocrine review clinic.
Nine (6-9%) had lapsed for a number of years but were ascertained to be alive,
and up-to-date morbidity data was obtained from the family doctor. Only two
had left Northern Ireland. Thirty-six (27-0%) had died - 17 died outside
hospital and information was by death certification only; 19 (14.%5%) died in
hospital and in 12 of these an autopsy was carried out. Analysis of coded data
sheets for each patient was carried out by computer using the SPSS system.
The diagnosis of acromegaly was reached in all cases on clinical grounds. All
patients had a standard lateral skull X-ray. Radioimmunoassay for serum human
growth hormone became available after 1967 and has been carried out in the
endocrine laboratory at the Royal Victoria Hospital since that time.
RESULTS
Prevalence and incidence
Prevalence is the number of people in the community who have the condition.
In 1984 there were 95 people alive and known to have acromegaly out of
the 1,490,000 population of Northern Ireland (prevalence 6-3 per 100,000
population).
Incidence is the number of new cases per unit of population per year. One
hundred and thirty-one patients in 25 years represents 5 -5 patients per year for
Northern Ireland, or 0-38 patients per 100,000 population per year. It may be
that not all patients identified in Northern Ireland were referred to the Royal
Victoria Hospital in the early part of this time, but we can be sure from 1970
onwards ofcomplete notification: overthis 13 yearperiod there were 81 patients,
representing 6 -4 new cases of acromegaly per year, or 0-41 patients diagnosed
per 100,000 population per year.
Clinical features at diagnosis
The presenting features did not differ from those found in other larger series.2
There were 66 females and 65 males. We have excluded from this review some
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patients who were referred because of clinical resemblance to acromegaly (large
hands or prognathic jaw) in whom serum growth hormone levels were normal
and no radiological evidence compatible with acromegaly wasfound. The median
age at diagnosis was 40-49 years, the youngest was 1 1 and the oldest 71. The
clinical estimate of the mean duration of symptoms prior to diagnosis was about
10 years. Six patients were noted to have acromegalic clinical features during
treatment for a non -pituitary malignancy.
Cardiovascular disease at diagnosis
Forty
-twopatients (33%) were hypertensiveat diagnosis (blood pressure > 160/
95 mmHg), or already on antihypertensive treatment. An abnormal electro-
cardiograph (any reported abnormality) was found in 23 (25%) of 93 patients.
Cardiomegaly on routine chest X -ray was found in 18 (19%) of 95 patients.
Carbohydrate metabolism at diagnosis
Sixteen of 116 patients (14%) were diagnosed to be diabetic by oral glucose
tolerance test using the criteria in use at the time ofthe test. None ofthe other 15
patients had glycosuria at the time of diagnosis. Two others (1'7%) fell into the
impaired glucose tolerance category used since 1980.3 Of these 16 diabetic
patients, eight required insulin treatment to control hyperglycaemia, six were on
oral hypoglycaemic agents and two on diet only.
Other endocrine disorders at diagnosis
Only one patient had a close relative (sister) also known to be acromegalic. She
had been diagnosed and treated by surgical hypophysectomy in Glasgow, where
she had been living for some time and she has not been included in this analysis.
Using standard thyroid function tests available atthe time, two ofthe 114 patients
(2%) were shown to be hyperthyroid and two others were euthyroid having
previously been treated for hyperthyroidism; seven (6%) had secondary hypo-
thyroidism (absence of serum TSH rise or other evidence of panhypopituitarism)
and five (4%) had primary hypothyroidism (elevated serum TSH at the time
of diagnosis). Four patients were hypercalcaemic, of whom three were shown
to have primary hyperparathyroidism which was subsequently cured by
parathyroidectomy.
Detailed studies on hypothalamic/pituitary function have only been carried out
in recent years and in younger patients. Thirteen of 72 patients (18%) had
secondary hypogonadism at diagnosis, and sixof84 patients(7%) had secondary
hypoadrenalism. Serum prolactin measurements were only available at diagnosis
in34 patients. Nineofthese (27%) had aserum prolactin greaterthan 360 mU/I.
Radiography
Ninety,-three of 127 patients (73%) had an abnormality of the pituitary fossa on
lateral skull X -ray. Detailed measurements of pituitary size were not made, but
the radiological opinion was reached at weekly ward meetings with the same
radiologist (Dr J 0 Y Cole) for the major period of this review. Computerised
tomographic scanning of the pituitary fossa was available from 1980 and with
more precision from 1983: of 21 cases examined at diagnosis, three werejudged
entirely normal, 10 were consistent with an intrasellar adenoma and eight had an
extrasellar extension of an adenoma (seven suprasellar, one into the sphenoidal
sinus).
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Ophthalmology
A formal ophthalmic record of visual acuity at diagnosis was available in 97
patients; 89 (92%) were normal. In eight, visual acuity was abnormal, and was
less than 6/60 in one eye or worse in five patients. Perimetry was carried
out on 115 patients (initially with a simple confrontation perimeter, after 1972
with a Tubingen static perimeter). Visual fields were normal in 94 patients
(82%). Unilateral field loss was found in seven (6%) and bilateral loss in 14
patients (12%).
TREATMENT
Twelve patients (9 2%) have had no treatment diercted toward the pituitary.
Sixty-two have had only one single form of treatment (10 hypophysectomy, 34
radiotherapy and 18 bromocriptine only), 37 have had two separate episodes of
treatment, 17 have had three, and three have had four different treatment
episodes. In all, 199 treatments have been given to 119 patients.
Fifty-one patients (39%) have had external cobalt irradiation (usually 4,500
rads); 12 ofthese also had pituitary surgery and five received bromocriptine later.
Eleven patients (8%) had internal irradiation by Yttrium -90 implantation at the
time of hypophysectomy.4 Sixty patients had 78 hypophysectomy operations,
45 by the transfrontal route and 33 transsphenoidal. Repeat surgery was carried
out in 15 patients and three had a third exploration.
Ten of the 39 patients who received a single treatment with external radiation
became panhypopituitary during follow-up. The onset of hypopituitarism ranged
from 1 -17 years after irradiation. Five patients who received only pituitary-
directed radiotherapy developed visual complications which were shown to
be due to the radiation rather than to local pressure from further pituitary
enlargement.5 Temporary diabetes insipidus developed postoperatively after
hypophysectomy on 22 occasions - nine following transsphenoidal surgery
(27%)and 13 following transfrontal surgery(29%). Severe haemorrhage causing
abandonment of operation occurred in two attempted hypophysectomies, one
patient developing a subdural haematoma. Other operative complications were
infection of wound or bone flap in seven, deterioration in visual fields in two, and
single cases of aphasia and mild hemiplegia, loss of taste and smell, and third
nerve palsy. No patient received treatment for meningitis but one patient who
died suddenly of respiratory arrest associated with severe headache and pyrexia
one day postoperatively was suspected to have had overwhelming meningitis
despite lack of post-mortem confirmation of this diagnosis. Another patient
developed self-limiting CSF rhinorrhoea.
After brief experience with chlorpromazine (four patients),6 63 patients since
1972 have been treated with bromocriptine, usually as an adjunct to other
definitive therapy. Eighteen have been treated with bromocriptine only. Drug
intolerance occurred in seven patients; treatment was continued in three ofthese.
One patient developed acute gastrointestinal symptoms and died of a perforated
duodenal ulcer shortly after starting bromocriptine as adjunctive therapy.
MORBIDITY AND MORTALITY
Morbidity at six months
In the first six months after treatment (or after diagnosis in those who were not
treated) six patients died. There were two peri-operative deaths (one on the
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first day from possible overwhelming meningitis and one on the seventh day
from pulmonary embolus and cerebral infarction). Three untreated patients died
rapidly of malignancy (carcinoma of lung) and one died of a cerebrovascular
accident three months after pituitary radiotherapy. In three cases no data on six-
month review was recorded. None of the other nine untreated patients had any
appreciable morbidity at six months. Full assessment of residual pituitary function
was not in general carried out on the earlier patients, and replacement therapy
with cortisone acetate or hydrocortisone was generally started postoperatively.
Fifty-three of the 116 patients were taking adrenal steroids and 55 were taking
thyroxine at six months. Of the 21 patients operated on transfrontally as an initial
treatment, all were on replacement treatment, compared with 13 of the 15
operated on transsphenoidally. Only 19 (16%) were receiving androgen or
oestrogen replacement therapy. Blood pressure was elevated in 31 of the 125
patients alive at six months (25%).
Morbidity at last review
The case notes of all 125 patients who survived six months from diagnosis,
including those who had no treatment, were studied to ascertain morbidity at last
attendance or prior to death. Eighty-six patients were still under review and had
been seen within the last year. Nine patients, including two who had left Northern
Ireland, had lapsed from the clinic; information concerning their state of health
was obtained from their general practitioners. Morbidity prior to terminal illness
was ascertained from the case notes in the 30 patients who died. Twenty-one of
the 125 patients were judged still to have active acromegaly on the evidence of
persistently elevated serum GH.7 Sixty-three (50%) were either demonstrably
panhypopituitary or were established on replacement therapy. Forty -eight (38%)
had arthritis, predominantly destructive osteoarthritisofthelargejoints, especially
hips, knees and lumbar spine. There were two cases with rheumatoid arthritis
which produced widespread and particularly crippling disability. Forty -three
patients (34%) had ischaemic heart disease based on documented myocardial
infarction, or a history of angina and electrocardiographic changes. Forty-two
patients (33%) were hypertensive. Nineteen (15%) were diabetic. Nine had
had a cerebrovascular accident. Other medical problems, mostly not of major
significance, occurred in 28% of these patients. Nine patients (7%) admitted to
no symptoms or disabilities of any sort.
Mortality
By December 1984, 36 ofthe 131 patients had died. There were 12 deaths from
cardiovascular disease (five from acute myocardial infarction, three with an
episode of congestive cardiac failure, and four sudden deaths outside hospital
had been certified as due to myocardial infarction) and five deaths from cerebro-
vascular disease. Eleven patients died from a malignancy (see below). The two
early post-craniotomy deaths were due to pulmonary embolus and possible
overwhelming meningitis. Two older patients died of bronchopneumonia, tuber-
culous in one case. One young patient died in an orthopaedic hospital from
pulmonary embolus after tibial osteotomy to reduce excessive height. One
patient committed suicide 22 years after treatment. One died of acute adrenal
insufficiency having survived two years without taking replacement therapy
following treatment by radiotherapy and then transfrontal craniotomy in 1961.
One patient died of peritonitis after perforation of a duodenal ulcer while taking
bromocriptine.
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Malignant diseases
Fifteen of the 131 patients have been diagnosed to have a malignant tumour.
Four of these are still under surgical review, one having been treated for
breast carcinoma, one for renal cell carcinoma and two for transitional cell
bladder carcinoma. Four patients have died of carcinoma ofthe colon, three from
carcinoma of the bronchus and one each from carcinoma of breast, pancreas,
oesophagus and bile ducts.
Squamous cell skin carcinomas were successfully treated in two patients. Benign
epithelial tumours were found in six patients (four nasal polyps, one benign
tumour of the gum and one benign vocal cord polyp). Two patients had large
benign subcutaneous lipomas.
DISCUSSION
The epidemiology of acromegaly has not been easy to study as patients are often
referred long distances for consultation and management and many less severely
affected patients do not remain under long term review by the treatment centre.
In Newcastle.-upon-Tyne a retrospective survey of all known cases in the region
suggested an annual incidence of close to three new cases per million population
and a prevalence of diagnosed cases of up to 40 cases per million.' The Northern
Ireland experience is likely to be even more complete due to the geographical
isolation and the clinical referral of all patients to the regional endocrine, radio-
therapy and neurosurgical centres in Belfast. In addition, a central register of
acromegalic patients has been maintained for the past 28 years with the aim of
producing long term data. The overall annual incidence of newly-diagnosed
cases of about four per million population is somewhat higher than in Newcastle,
perhaps because that study was less successful in maintaining contact with the
more peripheral parts of their region. This figure would be equivalent to 200 new
cases per year in the United Kingdom (population about 50 million) or 1000 per
year in the USA (population 250 million).
Cause ofdeath
The London five-hospital review (1937-1967) of 55 deaths in 194 patients
showed a mortality almost twice that expected from the general population,8
with increased deaths from cardiovascular and respiratory disease in males and
cerebrovascular and respiratory disease in females. There was also an excess
mortalityfrom malignant neoplasms infemalesaged65-74 years. TheNewcastle
study' also showed a significantly higher mortality in males from cardiovascular,
cerebrovascular, respiratory and malignant diseases but in females only from
cerebrovascular causes. Both of these studies have suggestive evidence of lower
mortality in treated patients, but neither was able to produce incontrovertible
data. Even in a single centre in Northern Ireland there-has not been a consistent
therapeutic policy, due to the gradual introduction of new options such as
bromocriptine and transsphenoidal microsurgery.
A life,-table analysis of the 131 patients shows that 80 7% survived to 10 years,
63
-2% to 20 years and 37% to 30 years, which is similar to the life expectancy
for age- and sex-matched groups from the general population of Northern
Ireland.
An aetiological association between excessive growth hormone secretion and
malignant colonic tumours has been suggested by some authors,9 but Wright
et al 8 and Mustacchi and Shimken'0 found no increased morbidity from, or risk
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of, cancerin acromegalic patients. Alexanderetal' found anexcessofmalignancy
death in men only. We found a higher than expected mortality from malignant
tumours, but the numbers are too small for detailed statistical analysis.
Treatment options
The problem in assessing response to treatment with a very long term disorder
such as acromegaly is that the patient often survives for a longer time than the
clinical interest of the doctor who made the treatment decision. Both surgical
hypophysectomy and pituitary radiotherapy have been available at most centres
for the past 40 years, so that a truly "untreated" series for comparison does
not exist. Most analyses have been carried out to try to assess the effectiveness
ofoneor other newly-introduced technique or drug, such as 'conventional' radio -
therapy," bromocriptinel2 or transsphenoidal microsurgery.'3 The Acromegaly
Study Group in Germany have made the best attempt to compare primary
treatment with transsphenoidal surgery (with or without cryotherapy), Yttrium -90
implantation or bromocriptine, but their results are short term and based largely
on a single endocrinological evaluation six months after the treatment.'4
The short term complications of surgical treatment are well-documented and
probably depend both on the experience at the centre and the severity of the
disease process. Analysis of the morbidity at last review may be a more useful
indicator of the patient's health than short term post-treatment assessment of
growth hormone levels. This would be particularly valid ifthe long term morbidity
of the treated patient depended more on the degree and duration of the excess
growth hormone secretion prior to treatment than on the post-treatment growth
hormone value. The Northern Ireland experience would support this view;
although 21 patients (more than six months after treatment) were judged still to
have active acromegaly with excess growth hormone secretion, compared to 63
where pituitary function was effectively ablated, the prevalence of osteoarthritis
(50% vs 38%) and hypertension (33% vs 33%) was not noticeably different in
the two groups. Only 7 % of patients had no symptoms or disabilities of any sort,
although the great majority had been able to continue their normal occupation in
spite of acromegaly and its treatment.
This approach is not to argue against the most effective treatment possible to
reduce inappropriate growth hormone secretion, but rather to concentrate on the
disability caused by the pre-treatment phase of the disease. Relevant to this
aspect is whether the natural history of distinct forms of inappropriate growth
hormone secretion isdifferent. Analogy with theproblems of hyperprolactinaemia
would suggest that someacromegalic patients with large, predominantly chromo -
phobe adenomas would have a more protracted disease which was more resistant
toanyformofintervention than other patientswith smaller, more discrete pituitary
lesions. It has been suggested that these two histological forms of the disorder
may represent different aetiological entities15 rather than the larger adenoma
merely being a later stage in the evolution of the smaller lesion. If that is so, the
neurosurgical practice of considering the larger pituitary lesion as necessitating as
extensive a hypophysectomy as possible, employing additional cryotherapy or
local irradiation to achieve a panhypopituitary state may well be correct at the
present time. The smaller, more discrete eosinophilic 'adenoma' in the pituitary
may in some cases be removed while leaving normal residual pituitary tissue, but
this form of the disease may in any case be less aggressive.
Whatever endocrine treatment option is undertaken, the natural history of the
treated patient who avoids acute peri-operative problems is probably more
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dependent on the pre-treatment severity and underlying pathophysiology of the
disease, than on the immediate post-treatment assessment. It is now 100 years
since the initial recognition of acromegaly by Pierre Marie,'6 but the neuro-
endocrine basisofthisparticular disorderisstill elusiveand present-daytreatment
remains less than ideal.
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